Alpha-fetoprotein and Tumour Size Are Associated with Microvascular Invasion in Explanted Livers of Patients Undergoing Transplantation with Hepatocellular Carcinoma

Overview

Journal HPB (Oxford)

Publisher Elsevier

Specialty Gastroenterology

Date 2010 May 25

PMID 20495646

Citations 67

Authors

Patrick P McHugh

Jeffrey Gilbert

Santiago Vera

Alvaro Koch

Dinesh Ranjan

Roberto Gedaly

Affiliations

Soon will be listed here.

Abstract

Background: To determine factors associated with outcomes and microvascular invasion (MVI) in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC).

Methods: Between July 1996 and August 2008 at the Universities of Kentucky or Tennessee, LT recipients were retrospectively analysed.

Results: One hundred and one patients had HCC in the explanted liver; one patient was excluded because of fibrolamellar histology. Seventy-nine (79%) were male and 81 (81%) were older than 50. HCC was incidental in 32 patients (32%). Median follow-up was 31 months. Ten patients (10%) developed recurrence, which was associated with poor survival (P= 0.006). Overall 1-, 3-, and 5-year survival rates were 87%, 69% and 62%, respectively. Excluding patients with lymph node metastasis (LNM) or MVI yielded 91%, 81% and 75% survival at the same time points. MVI was independently associated with recurrence (OR 28.40, 95% CI 1.77-456.48, P= 0.018) and decreased survival (OR 4.70, 95% CI 1.24-17.80, P= 0.023), and LNM with decreased survival (OR 6.05, 95% CI 1.23-29.71, P= 0.027). Tumour size (OR 4.1, 95% CI 1.2-13.5, P= 0.013) and alpha-fetoprotein (AFP) > 100 (OR 5.0, 95% CI 1.4-18.1, P= 0.006) were associated with MVI.

Conclusions: MVI greatly increases the risk of recurrence and death after LT for HCC, and is strongly associated with tumour size and AFP > 100.

Citing Articles

Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma.

Aujla U, Syed I, Rafi K, Naveed A, Malik A, Khan M Cureus. 2025; 16(12):e75007.

PMID: 39749089 PMC: 11694041. DOI: 10.7759/cureus.75007.

Evaluating microvascular invasion in hepatitis B virus-related hepatocellular carcinoma based on contrast-enhanced computed tomography radiomics and clinicoradiological factors.

Xu Z, Qian G, Li Y, Lu J, Wei M, Bu X World J Gastroenterol. 2024; 30(45):4801-4816.

PMID: 39649551 PMC: 11606376. DOI: 10.3748/wjg.v30.i45.4801.

A new model based on preoperative AFP, albumin, and tumor burden score for predicting microvascular invasion in early-stage HCC.

Chang Y, Tsai M, Tsai C, Wang C, Lin C, Yen Y Am J Cancer Res. 2024; 14(10):4979-4988.

PMID: 39553207 PMC: 11560811. DOI: 10.62347/ZGRJ7827.

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.

Son B, Lee W, Kim H, Shin H, Park H Cell Death Dis. 2024; 15(9):696.

PMID: 39349424 PMC: 11442590. DOI: 10.1038/s41419-024-07077-8.

Clinical Nomogram Model for Pre-Operative Prediction of Microvascular Invasion of Hepatocellular Carcinoma before Hepatectomy.

Chen J, Chen Y, Hsieh K, Lee H, Chen C, Chen J Medicina (Kaunas). 2024; 60(9).

PMID: 39336451 PMC: 11433876. DOI: 10.3390/medicina60091410.

References

Colella G, De Carlis L, Rondinara G, Sansalone C, Belli L, Aseni P . Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation?. Transplant Proc. 1997; 29(1-2):492-4. DOI: 10.1016/s0041-1345(96)00221-7. View

Yao F, Ferrell L, Bass N, Watson J, Bacchetti P, Venook A . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6):1394-403. DOI: 10.1053/jhep.2001.24563. View

Olthoff K, Rosove M, Shackleton C, Imagawa D, Farmer D, Northcross P . Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg. 1995; 221(6):734-41; discussion 731-43. PMC: 1234704. DOI: 10.1097/00000658-199506000-00012. View

Broelsch C, Frilling A, Malago M . Hepatoma--resection or transplantation. Surg Clin North Am. 2004; 84(2):495-511, x. DOI: 10.1016/j.suc.2003.11.001. View

Klintmalm G . Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998; 228(4):479-90. PMC: 1191521. DOI: 10.1097/00000658-199810000-00005. View

Lohe F, Angele M, Rentsch M, Graeb C, Gerbes A, Lohrs U . Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant. 2007; 21(6):696-701. DOI: 10.1111/j.1399-0012.2007.00707.x. View

Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K . Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol. 2008; 34(8):900-905. DOI: 10.1016/j.ejso.2008.01.031. View

Iwatsuki S, Gordon R, Shaw Jr B, Starzl T . Role of liver transplantation in cancer therapy. Ann Surg. 1985; 202(4):401-7. PMC: 1250934. DOI: 10.1097/00000658-198510000-00001. View

Durazo F, Blatt L, Corey W, Lin J, Han S, Saab S . Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23(10):1541-8. DOI: 10.1111/j.1440-1746.2008.05395.x. View

10.

Marubashi S, Dono K, Sugita Y, Asaoka T, Hama N, Gotoh K . Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2006; 38(10):3640-2. DOI: 10.1016/j.transproceed.2006.10.067. View

11.

Pawlik T, Delman K, Vauthey J, Nagorney D, Ng I, Ikai I . Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005; 11(9):1086-92. DOI: 10.1002/lt.20472. View

12.

Island E, Pomposelli J, Pomfret E, Gordon F, Lewis W, Jenkins R . Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg. 2005; 140(4):353-8. DOI: 10.1001/archsurg.140.4.353. View

13.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

14.

Sotiropoulos G, Malago M, Molmenti E, Losch C, Lang H, Frilling A . Hilar lymph nodes sampling at the time of liver transplantation for hepatocellular carcinoma: to do or not to do? Meta-analysis to determine the impact of hilar lymph nodes metastases on tumor recurrence and survival in patients with hepatocellular.... Transpl Int. 2007; 20(2):141-6. DOI: 10.1111/j.1432-2277.2006.00412.x. View

15.

Figueras J, Ibanez L, Ramos E, Jaurrieta E, Pardo F, Mir J . Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl. 2001; 7(10):877-83. DOI: 10.1053/jlts.2001.27856. View

16.

Shetty K, Timmins K, Brensinger C, Furth E, Rattan S, Sun W . Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004; 10(7):911-8. DOI: 10.1002/lt.20140. View

17.

Llovet J, Mas X, Aponte J, Fuster J, Navasa M, Christensen E . Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002; 50(1):123-8. PMC: 1773063. DOI: 10.1136/gut.50.1.123. View

18.

Esnaola N, Lauwers G, Mirza N, Nagorney D, Doherty D, Ikai I . Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002; 6(2):224-32; discussion 232. DOI: 10.1016/s1091-255x(01)00015-4. View

19.

Helton W, Di Bisceglie A, Chari R, Schwartz M, Bruix J . Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg. 2003; 7(3):401-11. DOI: 10.1016/s1091-255x(02)00161-0. View

20.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View